ACSS2 and leukemia: We highlight herein that HDACi, Class I HDACs, promoted stroma-dependent protection possibly affecting nuclear acetate levels to support drug resistance in leukemia, a mechanism mirrored in bacterial acetyl coA synthetase (acs) by switching to acetate in developing antibiotic resistance [55].